Articles citing this paper
Human papillomavirus prevalence to age 60 years among Australian women prevaccination
Julia M. L. Brotherton A B I , John R. Condon C , Peter B. McIntyre D , Sepehr N. Tabrizi E F G H , Michael Malloy A B , Suzanne M. Garland E F G H and on behalf of the WHINURS study group
+ Author Affiliations
- Author Affiliations
A National HPV Vaccination Program Register, PO Box 310, East Melbourne, Vic. 8002, Australia.
B School of Population and Global Health, Level 4, 207 Bouverie Street, The University of Melbourne, Vic. 3010, Australia.
C Menzies School of Health Research, PO Box 41096, Casuarina, NT 0811, Australia.
D National Centre for Immunisation Research and Surveillance, University of Sydney and The Children’s Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia.
E Regional World Health Organisation Human Papillomavirus Laboratory Network, Department of Microbiology and Infectious Diseases, The Royal Women’s Hospital, Locked Bag 300, Grattan Street and Flemington Road, Parkville, Vic. 3052, Australia.
F Department of Obstetrics and Gynaecology, University of Melbourne, The Royal Women’s Hospital, Locked Bag 300, Grattan Street and Flemington Road, Parkville, Vic. 3052, Australia.
G Department of Microbiology, Royal Children’s Hospital, 50 Flemington Road, Parkville, Vic. 3052, Australia.
H Murdoch Childrens Research Institute, The Royal Children’s Hospital, Flemington Road, Parkville, Vic. 3052, Australia.
I Corresponding author. Email: jbrother@vcs.org.au
Sexual Health 12(4) 353-359 https://doi.org/10.1071/SH15035
Submitted: 4 March 2015 Accepted: 15 April 2015 Published: 1 June 2015
Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination
Machalek Dorothy A,
Garland Suzanne M,
Brotherton Julia M L,
Bateson Deborah,
McNamee Kathleen,
Stewart Mary,
Rachel Skinner S,
Liu Bette,
Cornall Alyssa M,
Kaldor John M, Tabrizi Sepehr N
The Journal of Infectious Diseases. 2018 217(10). p.1590
Age-specific HPV prevalence among 116,052 women in Australia’s renewed cervical screening program: A new tool for monitoring vaccine impact
Brotherton Julia ML.,
Hawkes David,
Sultana Farhana,
Malloy Michael J.,
Machalek Dorothy A.,
Smith Megan A.,
Garland Suzanne M., Saville Marion
Vaccine. 2019 37(3). p.412
Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program
Garland Suzanne M.,
Cornall Alyssa M.,
Brotherton Julia M.L.,
Wark John D.,
Malloy Michael J., Tabrizi Sepehr N.
Vaccine. 2018 36(23). p.3221
Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia
Wnukowski-Mtonga Peter,
Jayasinghe Sanjay,
Chiu Clayton,
Macartney Kristine,
Brotherton Julia,
Donovan Basil,
Hall Madeline,
Smith David W,
Peterson Karen,
Campbell-Lloyd Sue,
Selvey Christine,
Giles Michelle,
Kaldor John, Marshall Helen
Communicable Diseases Intelligence. 2020 44
Reply to San Giorgi and Dikkers
Donovan Basil,
Callander Denton, Stanley Margaret
The Journal of Infectious Diseases. 2018 217(9). p.1506
Quadrivalent human papillomavirus vaccination successfully reduces the prevalence of vaccine-targeted genotypes in a young, vaccine-eligible-age sample of Australian females
Subasinghe Asvini K.,
Wark John D.,
Phillips Samuel,
Cornall Alyssa,
Brotherton Julia M. L., Garland Suzanne M.
Sexual Health. 2020 17(6). p.510
Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screening
Velentzis Louiza S.,
Hawkes David,
Caruana Michael,
Brotherton Julia ML.,
Smith Megan A.,
Roeske Lara,
Karim Khurram A.,
Garland Suzanne M.,
Wrede C. David,
Tan Jeffery,
Wheeler Cosette,
Castle Philip E.,
Saville Marion, Canfell Karen
Tumour Virus Research. 2023 15 p.200255
